Cargando…

Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer

OBJECTIVES: To evaluate risk of a second cancer and associated survival times in United States women with diagnosis of cancer. METHODS: The Surveillance Epidemiology and End Results (SEER) database was queried for 2 cohorts of women aged 18 - 89 with either an index gynecologic or non-gynecologic ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Corey, Logan, Ruterbusch, Julie, Shore, Ron, Ayoola-Adeola, Martins, Baracy, Michael, Vezina, Alex, Winer, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983878/
https://www.ncbi.nlm.nih.gov/pubmed/35402231
http://dx.doi.org/10.3389/fonc.2022.842441
_version_ 1784682054436257792
author Corey, Logan
Ruterbusch, Julie
Shore, Ron
Ayoola-Adeola, Martins
Baracy, Michael
Vezina, Alex
Winer, Ira
author_facet Corey, Logan
Ruterbusch, Julie
Shore, Ron
Ayoola-Adeola, Martins
Baracy, Michael
Vezina, Alex
Winer, Ira
author_sort Corey, Logan
collection PubMed
description OBJECTIVES: To evaluate risk of a second cancer and associated survival times in United States women with diagnosis of cancer. METHODS: The Surveillance Epidemiology and End Results (SEER) database was queried for 2 cohorts of women aged 18 - 89 with either an index gynecologic or non-gynecologic cancer diagnosed between 1992 – 2017. Index cases were followed to determine if a second primary cancer was subsequently diagnosed; defined according to SEER multiple primary and histology coding rules. Standard Incident Ratios (SIR) and latency intervals between index diagnosis and second primary diagnosis were evaluated. Among those who developed a second primary cancer, median survival times from diagnosis of second primary cancer were also calculated. RESULTS: Between 1992 – 2017, 227,313 US women were diagnosed with an index gynecological cancer and 1,483,016 were diagnosed with an index non-gynecologic cancer. Among patients with index gynecologic cancer, 7.78% developed a non-gynecologic subsequent primary cancer. The risk of developing any non-gynecologic cancer following an index gynecologic cancer was higher than the risk in the general population (SIR 1.05, 95% CI 1.04 - 1.07). Organs especially at risk were Thyroid (SIR 1.45), Colon and Rectum (SIR 1.23), and Urinary System (SIR 1.33). Among women diagnosed with an index non-gynecologic cancer, 0.99% were diagnosed with a subsequent gynecologic cancer. The risk of developing a gynecologic cancer following a non-gynecologic cancer was also elevated compared to the average risk of the general population (SIR 1.05, 1.03 - 1.07), with uterine cancer having the highest SIR of 1.13. CONCLUSION: The risk of a developing a second primary cancer and the corresponding survival time is based on the order and site of the index and subsequent cancer. Surveillance guidelines should be examined further to optimize survivorship programs.
format Online
Article
Text
id pubmed-8983878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89838782022-04-07 Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer Corey, Logan Ruterbusch, Julie Shore, Ron Ayoola-Adeola, Martins Baracy, Michael Vezina, Alex Winer, Ira Front Oncol Oncology OBJECTIVES: To evaluate risk of a second cancer and associated survival times in United States women with diagnosis of cancer. METHODS: The Surveillance Epidemiology and End Results (SEER) database was queried for 2 cohorts of women aged 18 - 89 with either an index gynecologic or non-gynecologic cancer diagnosed between 1992 – 2017. Index cases were followed to determine if a second primary cancer was subsequently diagnosed; defined according to SEER multiple primary and histology coding rules. Standard Incident Ratios (SIR) and latency intervals between index diagnosis and second primary diagnosis were evaluated. Among those who developed a second primary cancer, median survival times from diagnosis of second primary cancer were also calculated. RESULTS: Between 1992 – 2017, 227,313 US women were diagnosed with an index gynecological cancer and 1,483,016 were diagnosed with an index non-gynecologic cancer. Among patients with index gynecologic cancer, 7.78% developed a non-gynecologic subsequent primary cancer. The risk of developing any non-gynecologic cancer following an index gynecologic cancer was higher than the risk in the general population (SIR 1.05, 95% CI 1.04 - 1.07). Organs especially at risk were Thyroid (SIR 1.45), Colon and Rectum (SIR 1.23), and Urinary System (SIR 1.33). Among women diagnosed with an index non-gynecologic cancer, 0.99% were diagnosed with a subsequent gynecologic cancer. The risk of developing a gynecologic cancer following a non-gynecologic cancer was also elevated compared to the average risk of the general population (SIR 1.05, 1.03 - 1.07), with uterine cancer having the highest SIR of 1.13. CONCLUSION: The risk of a developing a second primary cancer and the corresponding survival time is based on the order and site of the index and subsequent cancer. Surveillance guidelines should be examined further to optimize survivorship programs. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8983878/ /pubmed/35402231 http://dx.doi.org/10.3389/fonc.2022.842441 Text en Copyright © 2022 Corey, Ruterbusch, Shore, Ayoola-Adeola, Baracy, Vezina and Winer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Corey, Logan
Ruterbusch, Julie
Shore, Ron
Ayoola-Adeola, Martins
Baracy, Michael
Vezina, Alex
Winer, Ira
Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title_full Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title_fullStr Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title_full_unstemmed Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title_short Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer
title_sort incidence and survival of multiple primary cancers in us women with a gynecologic cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983878/
https://www.ncbi.nlm.nih.gov/pubmed/35402231
http://dx.doi.org/10.3389/fonc.2022.842441
work_keys_str_mv AT coreylogan incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT ruterbuschjulie incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT shoreron incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT ayoolaadeolamartins incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT baracymichael incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT vezinaalex incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer
AT winerira incidenceandsurvivalofmultipleprimarycancersinuswomenwithagynecologiccancer